The history and future of targeting cyclin-dependent kinases in cancer therapy
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies. In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle. Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events. Translating this knowledge into successful clinical development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clinical trials. Here, we review the biology of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clinical results of CDK inhibitors. We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like palbociclib, these orally-bioavailable and highly selective CDK4/6-targeting agents exhibit IC50 values in the low nanomolar range, whereas other CDK family members are far less sensitive (1, 88, 89).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Such pan-CDK inhibitors had limited success, due in part to the dose limiting toxicities that hampered their use (Asghar et al., 2015).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“More than two decades after discovery of CDK4 and CDK6, drugs inhibiting their activities are now demonstrating significant efficacy in cancer treatment [for other recent reviews, see (1-3)].”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Cited by
Items 501–600 of 1,002
Yano, S., Tazawa, H., Kagawa, S., Fujiwara, T., & Hoffman, R. M. (2020) · Cancers · doi:10.3390/cancers12092655 · Cited by 40
LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells
Ma, Y., Xu, R., Liu, X., Zhang, Y., Li, S., Qiu, X., Cai, S., Zhou, S., Xie, Y., Li, A., et al. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.51256 · Cited by 40
“Abnormal cell cycle progression causes unrestricted cell division, leading to continuous proliferation, and represents a key driver of carcinogenesis[24].”
BackgroundVymětalová, L., Havlíček, L., Šturc, A., Skrášková, Z., Jorda, R., Pospíšil, T., Strnad, M., & Kryštof, V. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.011 · Cited by 40
“More potent compounds were developed soon afterward, and several were investigated in Phase II-III clinical trials [2].”
BackgroundNeoadjuvant endocrine therapy in breast cancer: current role and future perspectives
Barroso‐Sousa, R., Silva, D. D. F. R., Alessi, J. V. M., & Mano, M. S. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.609 · Cited by 40
“Cyclin-dependent kinases (CDKs) are critical regulatory enzymes that regulate all cell cycle transitions, making them interesting targets in BC [63].”
BackgroundPromotion of Myoblast Differentiation by Fkbp5 via Cdk4 Isomerization
Ruiz-Estevez, M., Staats, J., Paatela, E., Munson, D., Katoku-Kikyo, N., Yuan, C., Asakura, Y., Hostager, R., Kobayashi, H., Asakura, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.006 · Cited by 39
“Activation of Cdk4 and subsequent phosphorylation of Rb play a central role in deciding whether cells proceed through the restriction point in the late G1 phase; cells are then committed to completing the cell cycle independently of mitogens (Asghar et al., 2015; Baker and Reddy, 2012; Bockstaele et al., 2006).”
BackgroundZhang, H., He, F., Gao, G., Sheng, L., Wei, Q., Hu, H., Wu, Z., Fang, M., & Wang, X. (2023) · Molecules · doi:10.3390/molecules28030943 · Cited by 39
“First-generation pan-CDK inhibitors and second-generation multiCDK inhibitors are poorly selective and have highly toxic side effects [52].”
BackgroundLi, W., Kawaguchi, K., Tanaka, S., He, C., Maeshima, Y., Suzuki, E., & Toi, M. (2023) · Communications Biology · doi:10.1038/s42003-023-05433-6 · Cited by 40
Ono, K., Banno, H., Okaniwa, M., Hirayama, T., Iwamura, N., Hikichi, Y., Murai, S., Hasegawa, M., Hasegawa, Y., Yonemori, K., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.02.038 · Cited by 40
Ghanem, N. M., Farouk, F., George, R. F., Abbas, S. E.-S., & El-Badry, O. M. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.07.006 · Cited by 39
PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer
Duan, H., Lei, Z., Xu, F., Pan, T., Lu, D., Ding, P., Zhu, C., Pan, C., & Zhang, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00790 · Cited by 39
“Moreover, CDK2 is the pivotal cell cycle regulator in the S phase and G2 phase (36).”
BackgroundIdentification of co-expression modules and potential biomarkers of breast cancer by WGCNA
Jia, R., Zhao, H., & Jia, M. (2020) · Gene · doi:10.1016/j.gene.2020.144757 · Cited by 39
Knudsen, E. S., Shapiro, G. I., & Keyomarsi, K. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281085 · Cited by 39
Self-citationTranscriptional cyclin-dependent kinases: Potential drug targets in cancer therapy
Liu, Y., Fu, L., Wu, J., Liu, M., Wang, G., Liu, B., & Zhang, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114056 · Cited by 39
Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb
Egger, J. V., Lane, M. V., Antonucci, L., Dedi, B., & Krucher, N. A. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1235668 · Cited by 39
Modeling and Targeting MYC Genes in Childhood Brain Tumors
Hutter, S., Bolin, S., Weishaupt, H., & Swartling, F. J. (2017) · Genes · doi:10.3390/genes8040107 · Cited by 39
“These interactions exemplify the intricate relationship between MYC and CDKs, and demonstrate a potential benefit from disrupting these feedback loops therapeutically, since CDK/cyclin complexes are also found frequently deregulated in cancers [126].”
Clinical study of genomic drivers in pancreatic ductal adenocarcinoma
Barrett, M. T., Deiotte, R., Lenkiewicz, E., Malasi, S., Holley, T., Evers, L., Posner, R. G., Jones, T., Han, H., Sausen, M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.209 · Cited by 39
“The development of small molecule inhibitors of CDKs has shown promise in clinical trials (Asghar et al, 2015; Finn et al, 2015).”
BackgroundTonouchi, E., Gen, Y., Muramatsu, T., Hiramoto, H., Tanimoto, K., Inoue, J., & Inazawa, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-22767-y · Cited by 39
Translational Advances in Oncogene and Tumor-Suppressor Gene Research
Stojchevski, R., Sutanto, E. A., Sutanto, R., Hadzi‐Petrushev, N., Mladenov, M. I., Singh, S. P., Sinha, J. K., Ghosh, S., Yarlagadda, B., Singh, K. K., et al. (2025) · Cancers · doi:10.3390/cancers17061008 · Cited by 38
“…genes required for the G 1 /S transition, such as cyclin E ( CCNE ), cyclin A ( CCNA ), thereby preventing premature cell-cycle progression in G 1 [32,37,38]. or CDK4, translocation of CDK6, and deletions of INK4 proteins are key events disrupting cell-cycle control and contributing to…”
Expression and Clinical Role of Cdc5L as a Novel Cell Cycle Protein in Hepatocellular Carcinoma
Qiu, H., Zhang, X., Ni, W., Shi, W., Fan, H., Xu, J., Chen, Y., Ni, R., & Tao, T. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3937-9 · Cited by 38
Lasheen, S., Shohdy, K. S., Kassem, L. M. H., & Abdel-Rahman, O. M. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1355242 · Cited by 38
“It is noteworthy that the high toxicity associated with cyclin-dependent kinases (referred as pan-CDK inhibitors) hampered the pipeline of those agents for decades [22].”
BackgroundWatson, G. A., Deac, O. M., Aslam, R., O’Dwyer, R., Tierney, A., Sukor, S., & Kennedy, J. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.09.002 · Cited by 38
Huang, S., Zhang, C., Sun, C., Hou, Y., Zhang, Y., Tam, N. L., Wang, Z., Yu, J., Huang, B., Zhuang, H., et al. (2020) · Aging · doi:10.18632/aging.102797 · Cited by 38
“Therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies [25].”
BackgroundHow selective are clinical CDK4/6 inhibitors?
Hendrychová, D., Jorda, R., & Kryštof, V. (2020) · Medicinal Research Reviews · doi:10.1002/med.21769 · Cited by 38
“It can be also evaded by the upregulation of upstream pathways, which leads to Rb hyperphosphorylation.(13,32) Because of the multifunctional nature of Rb, which in complex with E2F transcription factors represses hundreds of genes involved in”
BackgroundInfluentialPhosphorylation of a Human Microprotein Promotes Dissociation of Biomolecular Condensates
Na, Z., Luo, Y., Cui, D. S., Khitun, A., Smelyansky, S. R., Loria, J. P., & Slavoff, S. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c05386 · Cited by 38
Anti-cancer drug molecules targeting cancer cell cycle and proliferation
Patra, D., Bhavya, K., Ramprasad, P., Kalia, M., & Pal, D. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.011 · Cited by 38
Kwak, A., Choi, J., Lee, M., Oh, H., Cho, S., Yoon, G., Liu, K., Chae, J., & Shim, J. (2019) · Molecules · doi:10.3390/molecules24224055 · Cited by 38
“Cell growth processes contain the cell cycle’s promotion [16].”
BackgroundNegative regulation of type I IFN signaling by phosphorylation of STAT2 on T387
Wang, Y., Jing, N., Willard, B. B., Wang, X., Yang, J. B., & Stark, G. R. (2016) · The EMBO Journal · doi:10.15252/embj.201694834 · Cited by 37
“Co-administration of a CDK inhibitor and type I IFN might be a novel strategy for treating cancers such as melanoma, which respond significantly to this therapy (Asghar et al , 2015), and for treating multiple sclerosis and virus infections.”
Cell Cycle Regulation in Treatment of Breast Cancer
Cai, Z., & Liu, Q. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_12 · Cited by 37
Lagarde, N., Rey, J., Gyulkhandanyan, A., Tufféry, P., Miteva, M. A., & Villoutreix, B. O. (2018) · Oncotarget · doi:10.18632/oncotarget.25966 · Cited by 39
“CDK2 is a member of the cyclin-dependent kinases family that is involved in cell replication and tumor growth, and is known to be a promising therapeutic target for cancer therapy [36].”
BackgroundCyclin-dependent kinase inhibitors for the treatment of lung cancer
Qin, A., Reddy, H. G., Weinberg, F. D., & Kalemkerian, G. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1738385 · Cited by 37
“Cyclin D1 protein over-expression, gene translocation and gene amplification, which are present in many different tumor types, lead to constitutive activation of CDK4/6 [11].”
BackgroundPhosphoprotein-based biomarkers as predictors for cancer therapy
Carter, A. M., Tan, C., Pozo, K., Telange, R., Molinaro, R., Guo, A., Rosa, E. D., Martinez, J. O., Zhang, S., Kumar, N., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2010103117 · Cited by 37
Pang, W., Li, Y., Guo, W., & Shen, H. (2020) · PubMed · Cited by 37
Gao, L., Xia, L., Ji, W., Zhang, Y., Xia, W., & Lü, S. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101148 · Cited by 37
NCAPD2 promotes breast cancer progression through E2F1 transcriptional regulation of CDK1
He, J., Gao, R., Yang, J., Li, F., Fu, Y., Cui, J., Liu, X., Huang, K., Guo, Q., Zhou, Z., et al. (2022) · Cancer Science · doi:10.1111/cas.15347 · Cited by 37
Ma, S., Liu, J., & Zhang, J. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104658 · Cited by 38
“It has also been found that eIF3d overexpression decreased the expression of proliferation, metastasis, and angiogenesis-related markers including cyclin A, PCAN, CDK1, N-cadherin, vimentin, VEGFA, and VEGFR2 (69, 92, 93).”
BackgroundFuruhashi, S., Bustos, M. A., Mizuno, S., Ryu, S., Naeini, Y. B., Bilchik, A. J., & Hoon, D. S. �. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00474-w · Cited by 37
“The cell cycle is regulated by cyclin-dependent kinase (CDK)- Cyclin complex, which are activated by the PI3K/Akt signaling 37 .”
The TRAPP complex mediates secretion arrest induced by stress granule assembly
Zappa, F., Wilson, C., Tullio, G. D., Santoro, M. C., Pucci, P., Monti, M., D'Amico, D. F., Pisonero‐Vaquero, S., Cegli, R. D., Romano, A., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2019101704 · Cited by 36
“The CDK protein kinase family is composed of 21 members (Malumbres, 2014) and available inhibitors have limited selectivity (Asghar et al., 2015).”
BackgroundA Photoaffinity Displacement Assay and Probes to Study the Cyclin‐Dependent Kinase Family
Grant, E. K., Fallon, D. J., Eberl, H. C., Fantom, K. G. M., Zappacosta, F., Messenger, C., Tomkinson, N. C. O., & Bush, J. T. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201906321 · Cited by 37
Legge, D., Chambers, A., Parker, C. T., Timms, P., Collard, T. J., & Williams, A. C. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa003 · Cited by 38
“Cancers acquire the ability for self-sustaining proliferation through a number of different means, including dysregulation of cell cycle, increased growth factor production, stimulation of cells within the microenvironment (resulting in increased proproliferative paracrine signalling) and the deregulation of growth fa…”
BackgroundYang, Z., Yin, W., Zhang, S., Shah, I., Zhang, B., Zhang, S., Li, Z., Lei, Z., & Ma, H. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b01094 · Cited by 36
Wang, Y., Chen, X., Yan, Y., Zhu, X., Liu, M., & Liu, X. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02121 · Cited by 36
Sharifi, M. N., Anandan, A., Grogan, P. T., & O'Regan, R. M. (2020) · Cancer · doi:10.1002/cncr.32931 · Cited by 36
“The CDK4/ CDK6/cyclin D complex itself is negatively regulated by endogenous CDK inhibitors: the INK4 and Cip/Kip protein families.(5) Components of the CDK4/CDK6/cyclin D/pRb pathway are commonly mutated in human cancers.”
BackgroundShan, W., Yuan, J., Hu, Z., Jiang, J., Wang, Y., Loo, N., Fan, L., Tang, Z., Zhang, T., Xu, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107884 · Cited by 36
“Cyclin-dependent kinases (CDKs) make up an evolutionarily conserved serine-threonine kinase family and have central roles in controlling cell division and modulating transcription (Asghar et al., 2015; Ferguson and Gray, 2018; Malumbres et al., 2009; O’Leary et al., 2016; Otto and Sicinski, 2017; Sherr et al., 2016).”
BackgroundShawky, A. M., Ibrahim, N. A., Abourehab, M. A. S., Abdalla, A. N., & Gouda, A. M. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1837124 · Cited by 36
“MS (EI): m/z (%) 466 ([Mþ 1]þ, 28), 465 ([M]þ, 16), 462 ([M3]þ, 18), 446 (15), 424 (17), 404 (37), 382 (57), 369 (42), 359 (22), 347 (15), 266 (46), 236 (27), 218 (18), 185 (16), 174 (25), 160 (19), 143 (4), 119 (22), 92 (100), 77 (29).”
Chaudhary, S., Pothuraju, R., Rachagani, S., Siddiqui, J. A., Atri, P., Mallya, K. B., Nasser, M. W., Sayed, Z., Lyden, E. R., Smith, L. M., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.004 · Cited by 36
Mohammed, E. Z., Mahmoud, W. R., George, R. F., Hassan, G. S., Omar, F. A., & Georgey, H. H. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105347 · Cited by 36
CDK Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Gupta, P., Narayanan, S., & Yang, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00009-2 · Cited by 36
Tumor Dormancy: Biologic and Therapeutic Implications
Balayan, V., & Guddati, A. K. (2022) · World Journal of Oncology · doi:10.14740/wjon1419 · Cited by 36
“Table 1 [5, 8-41] provides a user-friendly interface that summarizes publications that can be accessed to gain further understanding of tumor dormancy mechanisms that are also cited in the discussion.”
BackgroundCDK9 inhibitors in cancer research
Huang, Z. L., Wang, T., Wang, C., & Fan, Y. L. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00040g · Cited by 36
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
Koirala, N., Dey, N., Aske, J. C., & De, P. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126547 · Cited by 36
“The CDKi competitively binds to the ATP binding pocket of CDK 4/6 and prevents its association with CCND (1, 2, and 3), thereby, preserving Rb protein in its native (active) conformation (unphosphorylated state) that leads to G1 phase arrest, interference with cell cycle progression, and subsequent senescence/apoptosi…”
BackgroundYousuf, M., Alam, M., Shamsi, A., Κhan, P., Hasan, G. M., Haque, Q. M. R., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.156 · Cited by 37
Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion
Velez, B. C., Petrella, C., DiSalvo, K. H., Cheng, K., Kravtsov, R. L., Krasniqi, D., & Krucher, N. A. (2022) · Oncology Reports · doi:10.3892/or.2022.8469 · Cited by 36
“The discovery over 20 years ago that phosphorylation of Rb by CDKs promotes cellular proliferation led to the development of CDK inhibitors; however, the early compounds failed due to lack of specificity or had low affinity for CDK4/6 enzymes (2).”
CDC5L Promotes hTERT Expression and Colorectal Tumor Growth
Li, J., Zhang, N., Zhang, R., Sun, L., Yu, W., Guo, W., Gao, Y., Li, M., Liu, W., Liang, P., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000475916 · Cited by 36
CCNE1 amplification is associated with liver metastasis in gastric carcinoma
Kim, B., Shin, H. C., Heo, Y. J., Ha, S. Y., Jang, K., Kim, S. T., Kang, W. K., Lee, J., & Kim, K. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152434 · Cited by 36
Regulatory mechanisms and clinical perspectives of circRNA in digestive system neoplasms
Sun, Z., Chen, C., Su, Y., Wang, W., Yang, S., Zhou, Q., Wang, G., Li, Z., Song, J., Zhang, Z., et al. (2019) · Journal of Cancer · doi:10.7150/jca.31167 · Cited by 36
“As a target of miR-29b, CDK6 combined with cyclin promoted the cell cycle from G1 phase to S phase [35-37].”
BackgroundCDK14 involvement in proliferation migration and invasion of esophageal cancer
Chen, L., Wang, Y., Jiang, W., Ni, R., Wang, Y., & Ni, S. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.105 · Cited by 36
“Cyclin-dependent kinases (CDKs) are a family of 20 protein kinases that regulate cell cycle progression (Cdk1, Cdk2, Cdk3, Cdk4, and Cdk6), transcription (Cdk7, Cdk8, Cdk9, and Cdk10), differentiation (Cdk5), and other processes (5-7).”
BackgroundThe role of DOT1L in the proliferation and prognosis of gastric cancer
Song, Z., Wei, Z., Wang, Q., Zhang, X., Tao, X., Wu, N., Liu, X., & Qian, J. (2020) · Bioscience Reports · doi:10.1042/bsr20193515 · Cited by 36
RetractedQayoom, H., Mehraj, U., Sofi, S., Aisha, S., Almilaibary, A., Alkhanani, M., & Mir, M. A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01779-9 · Cited by 35
LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein
Cai, Z., Shi, Q., Li, Y., Jin, L., Li, S., Wong, L. L., Wang, J., Jiang, X., Zhu, M., Lin, J., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi3821 · Cited by 35
Luan, S., Zhong, H., Zhao, X., Yang, J., Jing, Y., Liu, D., & Zhao, L. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.023 · Cited by 35
Kang, M. Y., Kim, W., Jo, H.-R., Shin, Y.-J., Kim, M., & Jeong, J. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4424 · Cited by 35
“Therefore, CDKs are considered potential targets for anticancer therapies, by interfering with CDK functions to selectively interrupt cell cycle regulation in cancer cells (7).”
Yun, F., Cheng, C., Ullah, S., & Yuan, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112322 · Cited by 35
Huang, W., Abudureheman, T., Xia, J., Chu, L., Zhou, H., Zheng, W., Zhou, N., Shi, R., Li, M., Zhu, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641271 · Cited by 35
“CDK9 modulates the transcription elongation and mRNA maturation of genes but does not regulate cell cycle of cells (Asghar et al., 2015).”
BackgroundIwai, K., Nambu, T., Kashima, Y., Yu, J., Eng, K., Miyamoto, K., Kakoi, K., Gotou, M., Takeuchi, T., Kogame, A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf0197 · Cited by 35
“, fulvestrant) expand the therapeutic window of these anti-ER drugs: Highly improved efficacy of combination therapies has been clinically confirmed in patients with ERpositive breast cancer, whereas treatment with CDK4/6 inhibitors alone exhibited only modest responses in clinical trials (24, 25).”
Bautista, F., Paolettí, X., Rubino, J., Brard, C., Rezaï, K., Nebchi, S., André, N., Aerts, I., Carli, E. D., van Eijkelenburg, N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01152 · Cited by 35
Discovery and Optimization of Highly Selective Inhibitors of CDK5
Daniels, M. H., Malojcic, G., Clugston, S. L., Williams, B., Gal, M. C.-L., Pan-Zhou, X.-R., Venkatachalan, S. P., Harmange, J.-C., & Ledeboer, M. W. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02069 · Cited by 36
Knudsen, E. S., Schultz, E., Hamilton, D., Attwood, K. M., Edge, S. B., O’Connor, T. L., Levine, E. G., & Witkiewicz, A. K. (2022) · The Oncologist · doi:10.1093/oncolo/oyac089 · Cited by 36
Self-citationFeng, Y., Zhang, T., Zhang, Z., Liang, Y., Wang, H., Chen, Y., Yu, X., Song, X., Mao, Q., Xia, W., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06047-w · Cited by 35
“Cyclin B can interact with CDK1 to form a complex to control mitosis, and a higher expression of cyclin B can promote the activity of CDK1 [31].”
BackgroundPotential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
Fang, H., Huang, D., Yang, F., & Guan, X. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4612-y · Cited by 36
Cho, B. C., Dy, G. K., Govindan, R., Kim, D., Pennell, N. A., Zalcman, G., Besse, B., Kim, J.-H., Koca, G., Rajagopalan, P., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.022 · Cited by 35
JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21
Colleoni, B., Paternot, S., Pita, J. M. G., Bisteau, X., Coulonval, K., Davis, R. J., Raspé, E., & Roger, P. P. (2017) · Oncogene · doi:10.1038/onc.2017.7 · Cited by 35
Epigenetic assays for chemical biology and drug discovery
Gul, S. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0342-6 · Cited by 34
“Early drug discovery efforts for the CDKs did not yield selective inhibitors and as a consequence they were considered as being intractable for inhibition by small molecules [197].”
BackgroundHossian, A. K. M. N., Sajib, M. S., Tullar, P., Mikelis, C. M., & Mattheolabakis, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-28872-2 · Cited by 34
Sante, G. D., Pagé, J., Jiao, X., Nawab, O., Cristofanilli, M., Skordalakes, E., & Pestell, R. G. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1615889 · Cited by 34
Genetic determinants of the molecular portraits of epithelial cancers
Xia, Y., Fan, C., Hoadley, K. A., Parker, J. S., & Perou, C. M. (2019) · Nature Communications · doi:10.1038/s41467-019-13588-2 · Cited by 34
MASTL: A novel therapeutic target for Cancer Malignancy
Fatima, I., Singh, A. B., & Dhawan, P. (2020) · Cancer Medicine · doi:10.1002/cam4.3141 · Cited by 34
tRF-3013b inhibits gallbladder cancer proliferation by targeting TPRG1L
Zou, L., Yang, Y., Zhou, B., Li, W., Liu, K., Li, G., Miao, H., Song, X., Yang, J., Geng, Y., et al. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00398-6 · Cited by 35
“CDK2 is a key cyclindependent kinase that drives G1/S phase transition [47, 48].”
BackgroundCMGC Kinases in Health and Cancer
Chowdhury, I. M., Dashi, G., & Keskitalo, S. (2023) · Cancers · doi:10.3390/cancers15153838 · Cited by 34
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
Masci, D., Naro, C., Puxeddu, M., Urbani, A., Sette, C., Regina, G. L., & Silvestri, R. (2023) · Molecules · doi:10.3390/molecules28227513 · Cited by 34
“This activity blocks the growth inhibitory function of Rb; indeed, phospho-Rb (pRb) releases its grip and activates the transcription factors E2F, allowing the transcription of genes which are crucial for cell cycle progression to the S phase [77].”
BackgroundCancer TARGETases: DSB repair as a pharmacological target
Samadder, P., Aithal, R., Beláň, O., & Krejčí, L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.007 · Cited by 35
Ji, X., Humenik, J., Yang, D., & Liebhaber, S. A. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1255 · Cited by 34
“The CDKs are activated through pairing with specific cyclin partners (14,17).”
BackgroundInfluentialEl‐Azab, A. S., Abdel‐Aziz, A. A. ‐., Alsaif, N. A., Alkahtani, H. M., Alanazi, M. M., Obaidullah, A. J., Eskandrani, R. O., & Alharbi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104345 · Cited by 34
Gao, T., Sun, Y., Leng, P., Liu, D., Guo, Q., & Li, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1549520 · Cited by 34
Screening and Identification of Potential Prognostic Biomarkers in Adrenocortical Carcinoma
Xu, W.-H., Wu, J., Wang, J., Wan, F., Wang, H., Cao, D., Qu, Y.-Y., Zhang, H., & Ye, D. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00821 · Cited by 33
Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?
Wu, C. L., Yang, P., Liu, B., & Tang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s232464 · Cited by 34
Small-molecule PROTACs: Novel Agents for Cancer Therapy
Wan, Y., Yan, C., Gao, H. J., & Liu, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0340 · Cited by 33
Kazi, A., Chen, L., Xiang, S., Vangipurapu, R., Yang, H., Beato, F., Fang, B., Williams, T. M., Husain, K. M., Underwood, P. W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4781 · Cited by 33
Cell cycle regulation by complex nanomachines
Koliopoulos, M. G., & Alfieri, C. (2021) · FEBS Journal · doi:10.1111/febs.16082 · Cited by 33
Barlaam, B. C., Savi, C. D., Dishington, A. P., Drew, L., Ferguson, A. D., Ferguson, D., Gu, C., Hande, S. M., Hassall, L. A., Hawkins, J. L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01249 · Cited by 33
HNRNPU promotes the progression of hepatocellular carcinoma by enhancing CDK2 transcription
Liang, Y., Fan, Y., Liu, Y., & Fan, H. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112898 · Cited by 33
Benzimidazole‐based protein kinase inhibitors: Current perspectives in targeted cancer therapy
Ali, A. M., Tawfik, S. S., Mostafa, A. S., & Massoud, M. A. M. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14130 · Cited by 33
“Their activities are regulated by subunits called cyclins (Asghar et al., 2015; Morgan, 1995).”
BackgroundCyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
Johnston, S. R. D., Emde, A., Barrios, C. H., Srock, S., Neven, P., Martin, M., Cameron, D., Janni, W., & Gnant, M. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad045 · Cited by 33
Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
Zhang, Y., Shan, L., Tang, W., Ge, Y., Li, C., & Zhang, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00312 · Cited by 33
Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate
Li, Y., Guo, Q., Zhang, C., Huang, Z. L., Wang, T., Wang, X., Wang, X., Xu, G., Liu, Y., Yang, S., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.06.041 · Cited by 33
Willson, N.-L., Forder, R. E. A., Tearle, R. G., Williams, J. L., Hughes, R., Nattrass, G. S., & Hynd, P. (2018) · BMC Genomics · doi:10.1186/s12864-018-4723-9 · Cited by 33
“CDKN2B is known to weaken the binding of D-type cyclins and as well as interact with the catalytic domains of CDK4 and CDK6 as a potent inhibitor of kinase activity [39].”
BackgroundIorfida, M., Mazza, M., & Munzone, E. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s196240 · Cited by 33
Sarhan, M. O., El‐Karim, S. S. A., Anwar, M. M., Gouda, R. H., Zaghary, W. A., & Khedr, M. A. (2021) · Molecules · doi:10.3390/molecules26082273 · Cited by 33
Chemical Probes for Understudied Kinases: Challenges and Opportunities
Serafim, R. A. M., Elkins, J. M., Zuercher, W. J., Laufer, S., & Gehringer, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00980 · Cited by 33
CDK5 Functions as a Tumor Promoter in Human Lung Cancer
Zeng, J., Xie, S., Liu, Y., Shen, C., Song, X., Zhou, G.-L., & Wang, C. (2018) · Journal of Cancer · doi:10.7150/jca.25967 · Cited by 32
Shimonosono, M., Idichi, T., Seki, N., Yamada, Y., Arai, T., Arigami, T., Sasaki, K., Omoto, I., Uchikado, Y., Kita, Y., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4657 · Cited by 32
Metadata
- Authors
- Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S.
- Affiliations
- Institute of Cancer Research (GB)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Royal Marsden NHS Foundation Trust (GB)
- Corresponding author
- Knudsen, Erik S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-01-30
- Volume
- 14
- Issue
- 2
- Pages
- 130-146
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4480421
- OpenAlex
- W2057272791
- Cited by
- 1,767
- References
- 210
- Citations by year
- 2026: 100 · 2025: 157 · 2024: 157 · 2023: 170 · 2022: 180 · 2021: 200 · 2020: 185 · 2019: 148 · 2018: 150 · 2017: 161 · 2016: 112 · 2015: 46
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Consortium canadien en neurodégénérescence associée au vieillissement
- Cancer Research UK (16642)
- National Cancer Institute (R01CA129134, CA129134, CA188650, R01CA188650, CA163863, R01CA163863)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin-dependent kinases, cyclin-dependent kinase inhibitors, CDK4, CDK6, CDK2, CDK1, cell cycle regulation, G1 phase, chromosome stability, S phase, anticancer drug development, clinical trials, patient stratification, kinase selectivity
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Molecular Structure, Signal Transduction, Gene Expression Regulation, Neoplastic, Cyclin-Dependent Kinases, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.